Clinical trials protocol published in BMC Cancer journal | NexPlasmaGen
17279
post-template-default,single,single-post,postid-17279,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

Clinical trials protocol published in BMC Cancer journal

25 Apr Clinical trials protocol published in BMC Cancer journal

Posted at 15:35h in Uncategorized by
0 Likes

Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the clinical protocol for human safety trials initiated at CHUM with NexPlasmaGen medical technology for the treatment of breast cancer.

The published article can be viewed at the following link : Breast cancer PAINT: a first-in-human, dose-escalation study to determine the safety of Plasma Adjuvant INtra-operative Treatment in breast cancer patients | BMC Cancer | Full Text

These clinical trials began with 3 patients recruited in April 2025, including 1 patient already treated and the 2 other planned also this month. In addition to evaluating the safety of NexPlasmaGen technology, these trials assess its cosmetic effects and explore its effectiveness in destroying breast cancer cells on small areas of human breast tissue

ABOUT NEXPLASMAGEN

NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.

Contact

Valérie Léveillé, CEO/Founder

1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/

No Comments

Post A Comment